{"id":"asc22","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ASC22 targets programmed death ligand 1 (PD-L1), a key immune checkpoint protein expressed on tumor cells and immune cells. By blocking PD-L1 interactions with its receptors (PD-1 and B7.1), the drug relieves immune suppression in the tumor microenvironment, allowing T cells to recognize and attack cancer cells more effectively. This mechanism is designed to restore anti-tumor immunity in patients with PD-L1-expressing malignancies.","oneSentence":"ASC22 is a humanized monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 on immune cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:11:00.765Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Hepatocellular carcinoma (HCC)"}]},"trialDetails":[{"nctId":"NCT04465890","phase":"PHASE2","title":"A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2020-07-17","conditions":"Chronic Hepatitis b","enrollment":207},{"nctId":"NCT05330143","phase":"PHASE2","title":"Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2022-06-28","conditions":"HIV-1-infection, HIV Infections, PD-L1 Gene Mutation","enrollment":19},{"nctId":"NCT05129189","phase":"PHASE2","title":"Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2022-06-29","conditions":"HIV Infections","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ASC22","genericName":"ASC22","companyName":"Ascletis Pharmaceuticals Co., Ltd.","companyId":"ascletis-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASC22 is a humanized monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 on immune cells. Used for Non-small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}